EFFECT OF MAGNESIUM SULFATE COMBINED WITH MISOPROSTOL ON POSTPARTUM HEMORRHAGE AND HS-CRP, ANG-II, PGE2 IN PATIENTS WITH PREGNANCY-INDUCED HYPERTENSION SYNDROME

Objective: To study the effect of magnesium sulfate combined with misoprostol on postpartum hemorrhage and hs-CRP, Ang-II, PGE2 in PIH patients. Methods: A total of 159 PIH patients in our hospital from February 2018 to March 2019 were selected as research objects, and were enrolled into two groups according to different treatment methods. Among them, those treated by magnesium sulfate combined with misoprostol were taken as an intervention group (IG) (88 cases) and those treated by magnesium sulfate combined with oxytocin were regarded as a control group (CG) (71 cases). The clinical indexes (blood pressure, heart rate, respiration) and postpartum hemorrhage (time of the third stage of labor, effective control time of hemorrhage, amount of hemorrhage 2 h and 12 h after delivery) of patients in the two groups after treatment were observed. The efficacy of patients in both groups after treatment and the adverse reactions during treatment were recorded. Enzyme-linked immunosorbent assay ( ELISA) was used to detect the levels of hs-CRP,Ang-II and PGE2 before and after treatment. The predictive value of hs-CRP, Ang-II and PGE2 on the efficacy of patients was also analyzed. Results: Blood pressure, heart rate and respiration got better after treatment in the IG than those in the CG, and postpartum hemorrhage improved better after treatment in the IG than that in the CG. After treatment, the total effective rate in the IG was obviously higher than that in the CG, the incidence of adverse reactions in the IG was significantly lower than that in the CG, and hsCRP, Ang-II and PGE2 in the IG were dramatically lower than those in the CG. The predicted AUC of serum hs-CRP for ineffective treatment was 0.809, that of Ang-II for ineffective treatment was 0.810, and that of PGE2 for ineffective treatment was 0.896. Conclusion: Magnesium sulfate combined with misoprostol on PIH can improve the blood pressure of patients, reduce the risk of postpartum hemorrhage, and improve the expression of hs-CRP, Ang-II and PGE2 in serum.